flutamide has been researched along with trelstar in 49 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 20 (40.82) | 18.7374 |
| 1990's | 10 (20.41) | 18.2507 |
| 2000's | 13 (26.53) | 29.6817 |
| 2010's | 6 (12.24) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Couture, M; Couture, N; Dupont, A; Labrie, F; Rousseau, L | 1 |
| Dupont, A; Labrie, F; Lachance, R; St-Arnaud, R | 1 |
| Bélanger, A; Caron, S; Labrie, F; Lacoste, D | 1 |
| Bélanger, A; Dubé, D; Labrie, F; Lacoste, D | 1 |
| Labrie, F; Marchetti, B | 1 |
| Bélanger, A; Dupont, A; Labrie, F; Lacourcière, Y; Monfette, G; Monfette, JE | 1 |
| Givner, ML; Millard, OH | 1 |
| Belanger, A; Borsanyi, JP; Dupont, A; Emond, J; Giguere, M; Labrie, F; Lachance, R; Lacourciere, Y; Monfette, G | 1 |
| Bélanger, A; Brochu, M; Cusan, L; Dupont, A; Labrie, F | 1 |
| Belanger, A; Caron, S; Labrie, F; Lacoste, D; St-Arnaud, R | 1 |
| Belanger, A; Borsanyi, JP; Dupont, A; Emond, J; Giguere, M; Labrie, F; Lacourciere, Y; Monfette, G | 1 |
| Redding, TW; Schally, AV | 1 |
| Bélanger, A; Brun, D; Cusan, L; Dupont, A; Gagné, C; Giguère, M; Labrie, F; Lupien, PJ; Moorjani, S | 1 |
| Bélanger, A; Couture, J; Cusan, L; Dupont, A; Giasson, M; Labrie, F | 1 |
| Bélanger, A; Cusan, L; Dupont, A; Emond, J; Giguère, M; Labrie, C; Labrie, F; Lacourcière, Y; Monfette, G | 1 |
| Belanger, A; Bergeron, N; Borsanyi, JP; Cusan, L; Dupont, A; Emond, J; Giguere, M; Labrie, F; Lacourciere, Y | 1 |
| Belanger, A; Bergeron, N; Borsanyi, JP; Cusan, L; Dupont, A; Emond, J; Giguere, M; Labrie, F; Lacourciere, Y; Monfette, G | 1 |
| Belanger, A; Dupont, A; Labrie, F; Lachance, R | 1 |
| Belanger, A; Dupont, A; Kelly, SJ; Labrie, F; Lachance, R; St-Arnaud, R | 1 |
| Dupont, A; Labrie, F; Lachance, R; St Arnaud, R | 1 |
| Belanger, A; Dupont, A; Giguere, M; Labrie, F; Lachance, R | 1 |
| Derde, MP; Kaufman, L; Mattelaer, J; Oosterlinck, W | 1 |
| Cusan, L; Diamond, P; Dupont, A; Gomez, JL; Labrie, F; Lemay, M; Moore, S | 1 |
| Burger, CW; Greggi, S; Kenemans, P; van der Vange, N; Vermorken, JB | 1 |
| Giannoulis, G; Hadziyannis, SJ; Manesis, EK; Vafiadou, I; Zoumboulis, P | 1 |
| Cusan, L; Diamond, P; Dupont, A; Gomez, JL; Labrie, F | 1 |
| Bellas, C; Hernanz, I; Molina, JP; Montalbán, C; Moreno, MA | 1 |
| Balsa, J; Escobar-Morreale, HF; Pazos, F; Sancho, JM; Varela, C | 1 |
| Cusan, L; Dupont, A; Emond, J; Gomez, JL; Koutsilieris, M; Labrie, F; Suburu, R | 1 |
| Adami, S; Castello, R; Gatti, D; Moghetti, P; Muggeo, M; Negri, C; Rossini, M; Tosi, F; Zamberlan, N | 1 |
| Hedlund, PO; Henriksson, P | 1 |
| Hamano, S; Kinsui, H; Murakami, S; Oikawa, T; Shimazaki, J; Suzuki, N; Tanaka, M | 1 |
| Bertolini, L; Bonadio, AG; Catastini, M; Cecchi, M; Di Benedetto, A; Fiorentini, L; Ippolito, C; Pazzagli, I; Sepich, CA; Summonti, D | 1 |
| Caruso, A; De Leo, V; Fulghesu, AM; la Marca, A; Morgante, G; Pasqui, L; Talluri, B; Torricelli, M | 1 |
| Arango Toro, O; Bielsa Gali, O; Gelabert Mas, A; Griño Garreta, J; Lorente Garín, JA | 1 |
| Hammar, M; Lindberg, B; Spångberg, A; Spetz, AC; Varenhorst, E | 1 |
| Candas, B; Cusan, L; Gomez, JL; Labrie, F | 1 |
| Ala-Opas, M; Brekkan, E; Damber, JE; Damber, L; Hagerman, I; Haukaas, S; Hedlund, PO; Henriksson, P; Iversen, P; Pousette, A; Rasmussen, F; Salo, J; Vaage, S; Varenhorst, E | 1 |
| Cardi, A; Di Silverio, F; Gentile, V; Lucera, R; Mariotti, G; Monti, S; Sciarra, A; Voria, G | 1 |
| Groot, K; Letsch, M; Schally, AV; Stangelberger, A; Varga, JL | 1 |
| López Carrizosa, MC; Melchor Iñiguez, M; Pérez Casas, A; Pérez Vara, C; Rubio Rodríguez, MC; Samper, PM; Vallejo, C | 1 |
| Aguilera Tubet, C; Ballestero Diego, R; Roca Edreira, A; Villanueva Peña, A; Zubillaga Guerrero, S | 1 |
| Aus, G; Garmo, H; Hedlund, PO; Johansson, R; Robinson, D; Sandblom, G; Varenhorst, E | 1 |
| Armstrong, JG; Buckney, SJ; Cannon, ME; Dunne, MT; Finn, MA; Fitzpatrick, DA; Gillham, CM; O'Shea, CM; Taylor, JC; Thirion, PG | 1 |
| Juncà, J; Navarro, JT; Pérez-Montaña, A; Ribera, JM | 1 |
| Damber, JE; Hagerman, I; Hedlund, PO; Henriksson, P; Iversen, P; Johansson, R; Klarskov, P; Mogensen, P; Rasmussen, F; Varenhorst, E | 1 |
| Antes, G; Dahm, P; Grobe, HR; Kunath, F; Meerpohl, JJ; Motschall, E; Rücker, G; Wullich, B | 1 |
| Duensing, S; Grüllich, C; Hadaschik, BA; Höfner, T; Hohenfellner, M; Jäger, D; Pahernik, S; Vallet, S | 1 |
| Berglund, A; Hedlund, PO; Klaff, R; Sandblom, G; Varenhorst, E | 1 |
2 review(s) available for flutamide and trelstar
| Article | Year |
|---|---|
Combination therapy with flutamide and [D-Trp6, des-Gly-NH2(10)]LHRH ethylamide in stage C and D prostate cancer: today's therapy of choice--rationale and 5-year clinical experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Delayed-Action Preparations; Dihydrotestosterone; Flutamide; Follow-Up Studies; Gonadotropin-Releasing Hormone; Humans; Male; Orchiectomy; Prostate; Prostatic Neoplasms; Triptorelin Pamoate | 1988 |
Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Disease Progression; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Medication Adherence; Nitriles; Orchiectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Tosyl Compounds; Triptorelin Pamoate | 2014 |
17 trial(s) available for flutamide and trelstar
| Article | Year |
|---|---|
Advantages of the combination therapy in previously untreated and treated patients with advanced prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents; Buserelin; Clinical Trials as Topic; Combined Modality Therapy; Diethylstilbestrol; Flutamide; Follow-Up Studies; Gonadotropin-Releasing Hormone; Humans; Leuprolide; Male; Neoplasm Staging; Orchiectomy; Prostatic Neoplasms; Triptorelin Pamoate | 1986 |
Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in previously untreated patients with clinical stage D2 prostate cancer: today's therapy of choice.
Topics: Aged; Anilides; Clinical Trials as Topic; Combined Modality Therapy; Flutamide; Gonadotropin-Releasing Hormone; Humans; Male; Neoplasm Staging; Orchiectomy; Pain; Prostatic Neoplasms; Triptorelin Pamoate | 1988 |
Prognostic factors in advanced prostatic carcinoma treated with total androgen blockade. Flutamide with orchiectomy or with LHRH analogues. A Belgian multicentric study of 546 patients.
Topics: Aged; Analysis of Variance; Androgen Antagonists; Antineoplastic Agents, Hormonal; Castration; Combined Modality Therapy; Disease-Free Survival; Flutamide; Goserelin; Humans; Male; Middle Aged; Multivariate Analysis; Prognosis; Prostatic Neoplasms; Triptorelin Pamoate | 1995 |
Treatment of hepatocellular carcinoma with combined suppression and inhibition of sex hormones: a randomized, controlled trial.
Topics: Analysis of Variance; Androgens; Carcinoma, Hepatocellular; Double-Blind Method; Drug Therapy, Combination; Estradiol; Estrone; Female; Flutamide; Follicle Stimulating Hormone; Follow-Up Studies; Humans; Liver Neoplasms; Luteinizing Hormone; Male; Middle Aged; Neoplasm Staging; Placebos; Probability; Survival Rate; Tamoxifen; Time Factors; Triptorelin Pamoate | 1995 |
Major advantages of "early" administration of endocrine combination therapy in advanced prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Modality Therapy; Flutamide; Gonadotropin-Releasing Hormone; Humans; Male; Orchiectomy; Prostatic Neoplasms; Survival Analysis; Triptorelin Pamoate | 1993 |
Prospective randomized study comparing the long-acting gonadotropin-releasing hormone agonist triptorelin, flutamide, and cyproterone acetate, used in combination with an oral contraceptive, in the treatment of hirsutism.
Topics: Adult; Androgen Antagonists; Body Mass Index; Contraceptives, Oral, Hormonal; Cyproterone Acetate; Drug Therapy, Combination; Female; Flutamide; Hirsutism; Humans; Hyperandrogenism; Liver Function Tests; Luteolytic Agents; Prospective Studies; Triptorelin Pamoate | 1999 |
Spironolactone, but not flutamide, administration prevents bone loss in hyperandrogenic women treated with gonadotropin-releasing hormone agonist.
Topics: Adult; Bone and Bones; Bone Density; Bone Resorption; Female; Flutamide; Hirsutism; Humans; Polycystic Ovary Syndrome; Spironolactone; Triptorelin Pamoate | 1999 |
Parenteral estrogen versus total androgen ablation in the treatment of advanced prostate carcinoma: effects on overall survival and cardiovascular mortality. The Scandinavian Prostatic Cancer Group (SPCG)-5 Trial Study.
Topics: Aged; Alkaline Phosphatase; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cardiovascular Diseases; Estradiol; Estradiol Congeners; Flutamide; Humans; Injections, Intramuscular; Male; Orchiectomy; Prostatic Neoplasms; Survival Rate; Triptorelin Pamoate | 2000 |
[Endocrine therapy of stage D2 prostate cancer--comparison of drugs used for total androgen blockade].
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Castration; Chlormadinone Acetate; Combined Modality Therapy; Disease-Free Survival; Drug Therapy, Combination; Estrogens; Flutamide; Humans; Male; Middle Aged; Neoplasm Staging; Prostatic Neoplasms; Survival Rate; Triptorelin Pamoate | 2000 |
Hormonal and clinical effects of GnRH agonist alone, or in combination with a combined oral contraceptive or flutamide in women with severe hirsutism.
Topics: Adult; Amenorrhea; Androgen Antagonists; Contraceptives, Oral, Combined; Cyproterone Acetate; Estradiol; Estradiol Congeners; Estrone; Ethinyl Estradiol; Female; Flutamide; Follicle Stimulating Hormone; Gonadotropin-Releasing Hormone; Hirsutism; Humans; Luteinizing Hormone; Luteolytic Agents; Polycystic Ovary Syndrome; Progesterone Congeners; Prospective Studies; Triptorelin Pamoate | 2000 |
Prospective evaluation of hot flashes during treatment with parenteral estrogen or complete androgen ablation for metastatic carcinoma of the prostate.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Estradiol; Estradiol Congeners; Flutamide; Hot Flashes; Humans; Injections, Intramuscular; Male; Orchiectomy; Prostatic Neoplasms; Triptorelin Pamoate | 2001 |
Can combined androgen blockade provide long-term control or possible cure of localized prostate cancer?
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Therapy, Combination; Flutamide; Follow-Up Studies; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Longitudinal Studies; Male; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Treatment Outcome; Triptorelin Pamoate | 2002 |
Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer -- Scandinavian Prostatic Cancer Group (SPCG) Study No. 5.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cardiovascular Diseases; Disease Progression; Drug Therapy, Combination; Estradiol; Estradiol Congeners; Flutamide; Humans; Injections, Intravenous; Male; Orchiectomy; Prostatic Neoplasms; Triptorelin Pamoate | 2002 |
Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chromogranin A; Chromogranins; Flutamide; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Triptorelin Pamoate | 2003 |
A randomized trial (Irish clinical oncology research group 97-01) comparing short versus protracted neoadjuvant hormonal therapy before radiotherapy for localized prostate cancer.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Disease-Free Survival; Drug Administration Schedule; Flutamide; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prostate-Specific Antigen; Prostatic Neoplasms; Radiotherapy, Conformal; Risk Factors; Treatment Outcome; Triptorelin Pamoate | 2011 |
Significance of pretreatment cardiovascular morbidity as a risk factor during treatment with parenteral oestrogen or combined androgen deprivation of 915 patients with metastasized prostate cancer: evaluation of cardiovascular events in a randomized trial
Topics: Aged; Antineoplastic Agents, Hormonal; Cardiovascular Diseases; Combined Modality Therapy; Estradiol; Estrogens; Flutamide; Humans; Infusions, Parenteral; Male; Neoplasm Metastasis; Orchiectomy; Prognosis; Prostatic Neoplasms; Risk Factors; Triptorelin Pamoate | 2011 |
Predictors of early androgen deprivation treatment failure in prostate cancer with bone metastases.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Bone Neoplasms; Flutamide; Humans; Male; Middle Aged; Orchiectomy; Prospective Studies; Prostatic Neoplasms; Regression Analysis; Risk Factors; Treatment Failure; Triptorelin Pamoate | 2016 |
30 other study(ies) available for flutamide and trelstar
| Article | Year |
|---|---|
Effect of combined androgen blockade with an LHRH agonist and flutamide in one severe case of male exhibitionism.
Topics: Administration, Oral; Adult; Anilides; Dihydrotestosterone; Drug Therapy, Combination; Exhibitionism; Flutamide; Follow-Up Studies; Gender Identity; Gonadotropin-Releasing Hormone; Humans; Injections, Subcutaneous; Male; Masturbation; MMPI; Paraphilic Disorders; Sexual Behavior; Sperm Count; Sperm Motility; Testosterone; Triptorelin Pamoate | 1990 |
Stimulation of the circulating levels of glycoprotein hormone alpha-subunit after combined administration of a luteinizing hormone-releasing hormone (LHRH) agonist and flutamide in patients with cancer of the prostate.
Topics: Androgen Antagonists; Anilides; Carcinoma; Castration; Flutamide; Glycoprotein Hormones, alpha Subunit; Gonadotropin-Releasing Hormone; Humans; Luteinizing Hormone; Male; Osmolar Concentration; Peptide Fragments; Pituitary Hormones, Anterior; Prostatic Neoplasms; Stimulation, Chemical; Triptorelin Pamoate | 1986 |
Effect of 3-week treatment with [D-Trp6, des-Gly-NH10(2)]LHRH ethylamide, aminoglutethimide, ketoconazole or flutamide alone or in combination on testicular, serum, adrenal and prostatic steroid levels in the dog.
Topics: Adrenal Glands; Aminoglutethimide; Androgens; Animals; Dogs; Flutamide; Gonadotropin-Releasing Hormone; Ketoconazole; Male; Prostate; Testis; Triptorelin Pamoate | 1989 |
Effect of 2-week combination therapy with the luteinizing hormone-releasing hormone (LHRH) agonist [D-Trp6, des-Gly-NH2(10)]LHRH ethylamide and the antiandrogen flutamide on prostate structure and steroid levels in the dog.
Topics: Androgens; Anilides; Animals; Dogs; Drug Therapy, Combination; Estrogens; Flutamide; Gonadotropin-Releasing Hormone; Hormones; Male; Organ Size; Progestins; Prostate; Triptorelin Pamoate | 1989 |
Characteristics of flutamide action on prostatic and testicular functions in the rat.
Topics: Anilides; Animals; Flutamide; Follicle Stimulating Hormone; Gonadotropin-Releasing Hormone; Luteinizing Hormone; Male; Orchiectomy; Organ Size; Ornithine Decarboxylase; Prolactin; Prostate; Rats; Rats, Inbred Strains; Receptors, Adrenergic, beta; Receptors, FSH; Receptors, LH; Testis; Testosterone; Triptorelin Pamoate | 1988 |
[Combined anti-androgen treatment in adenocarcinoma of the prostate: first use of a new therapeutically efficacious principle in hormone-dependent cancer].
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents; Drug Therapy, Combination; Flutamide; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Imidazolidines; Male; Middle Aged; Neoplasms, Hormone-Dependent; Orchiectomy; Prostatic Neoplasms; Triptorelin Pamoate | 1986 |
Effect of surgical and biochemical castration and an antiandrogen on patients with stage D2 prostatic cancer: preliminary results.
Topics: Anilides; Flutamide; Gonadotropin-Releasing Hormone; Humans; Male; Orchiectomy; Prostatic Neoplasms; Triptorelin Pamoate | 1987 |
Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients.
Topics: Adenocarcinoma; Androgens; Anilides; Combined Modality Therapy; Evaluation Studies as Topic; Flutamide; Gonadotropin-Releasing Hormone; Humans; Male; Neoplasms, Hormone-Dependent; Orchiectomy; Prostatic Neoplasms; Receptors, Androgen; Triptorelin Pamoate | 1987 |
Endocrine effects of combined treatment with an LHRH agonist in association with flutamide in metastatic prostatic carcinoma.
Topics: Adenocarcinoma; Adrenal Cortex Hormones; Androgens; Androstane-3,17-diol; Androstenediol; Androstenedione; Androsterone; Anilides; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Dehydroepiandrosterone; Flutamide; Follicle Stimulating Hormone; Gonadotropin-Releasing Hormone; Humans; Hydrocortisone; Kinetics; Luteinizing Hormone; Male; Pregnenolone; Progesterone; Prolactin; Prostatic Neoplasms; Testosterone; Triptorelin Pamoate | 1988 |
The rise in testicular androgens during the first days of treatment with an LHRH agonist in the dog can be blocked by aminoglutethimide or ketoconazole.
Topics: Aldehyde-Lyases; Aminoglutethimide; Androgens; Animals; Cytochrome P-450 Enzyme Inhibitors; Dogs; Estradiol; Flutamide; Gonadotropin-Releasing Hormone; Ketoconazole; Luteinizing Hormone; Male; Pregnenolone; Progesterone; Steroid 17-alpha-Hydroxylase; Testis; Testosterone; Triptorelin Pamoate | 1988 |
Investigation of the combination of the agonist D-Trp-6-LH-RH and the antiandrogen flutamide in the treatment of Dunning R-3327H prostate cancer model.
Topics: Anilides; Animals; Body Weight; Cell Line; Drug Therapy, Combination; Flutamide; Gonadotropin-Releasing Hormone; Luteinizing Hormone; Male; Neoplasms, Hormone-Dependent; Organ Size; Prolactin; Prostate; Prostatic Neoplasms; Rats; Testis; Testosterone; Triptorelin Pamoate | 1985 |
Changes in plasma lipoproteins during various androgen suppression therapies in men with prostatic carcinoma: effects of orchiectomy, estrogen, and combination treatment with luteinizing hormone-releasing hormone agonist and flutamide.
Topics: Aged; Aged, 80 and over; Anilides; Apolipoproteins B; Combined Modality Therapy; Estrogens; Flutamide; Gonadotropin-Releasing Hormone; Humans; Lipids; Lipoproteins; Male; Middle Aged; Orchiectomy; Prostatic Neoplasms; Retrospective Studies; Triptorelin Pamoate | 1988 |
Plasma levels of hydroxy-flutamide in patients with prostatic cancer receiving the combined hormonal therapy: an LHRH agonist and flutamide.
Topics: Adult; Aged; Anilides; Antineoplastic Combined Chemotherapy Protocols; Flutamide; Gonadotropin-Releasing Hormone; Humans; Kinetics; Male; Middle Aged; Prostatic Neoplasms; Testosterone; Triptorelin Pamoate | 1988 |
Combination therapy with flutamide and [D-Trp6]LHRH ethylamide for stage C prostatic carcinoma.
Topics: Acid Phosphatase; Adenocarcinoma; Adrenal Cortex Hormones; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Delayed-Action Preparations; Flutamide; Gonadotropin-Releasing Hormone; Gonadotropins, Pituitary; Humans; Male; Middle Aged; Neoplasm Staging; Prostatic Neoplasms; Testosterone; Triptorelin Pamoate | 1988 |
Flutamide eliminates the risk of disease flare in prostatic cancer patients treated with a luteinizing hormone-releasing hormone agonist.
Topics: Acid Phosphatase; Aged; Anilides; Drug Therapy, Combination; Flutamide; Gonadotropin-Releasing Hormone; Humans; Luteinizing Hormone; Male; Prostatic Neoplasms; Testosterone; Triptorelin Pamoate | 1987 |
Loss of luteinizing hormone bioactivity in patients with prostatic cancer treated with an LHRH agonist and a pure antiandrogen.
Topics: Adenocarcinoma; Anilides; Animals; Biological Assay; Drug Therapy, Combination; Flutamide; Gonadotropin-Releasing Hormone; Humans; Luteinizing Hormone; Male; Mice; Prostatic Neoplasms; Radioimmunoassay; Testosterone; Triptorelin Pamoate | 1986 |
Serum luteinizing hormone (LH) biological activity in castrated patients with cancer of the prostate receiving a pure antiandrogen and in estrogen-pretreated patients treated with an LH-releasing hormone agonist and antiandrogen.
Topics: Aged; Anilides; Biological Assay; Combined Modality Therapy; Diethylstilbestrol; Drug Therapy, Combination; Flutamide; Gonadotropin-Releasing Hormone; Humans; Luteinizing Hormone; Male; Middle Aged; Orchiectomy; Prostatic Neoplasms; Radioimmunoassay; Time Factors; Triptorelin Pamoate | 1986 |
Long term treatment with luteinising hormone releasing hormone agonists and maintenance of serum testosterone to castration concentrations.
Topics: Bone Neoplasms; Buserelin; Flutamide; Gonadotropin-Releasing Hormone; Humans; Luteinizing Hormone; Male; Prostatic Neoplasms; Radioimmunoassay; Testosterone; Time Factors; Triptorelin Pamoate | 1985 |
Metastatic prostate cancer pulmonary nodules: beneficial effects of combination therapy and subsequent withdrawal of flutamide.
Topics: Acid Phosphatase; Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bone and Bones; Flutamide; Gonadotropin-Releasing Hormone; Humans; Lung Neoplasms; Male; Middle Aged; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Radionuclide Imaging; Sputum; Tomography, X-Ray Computed; Triptorelin Pamoate | 1994 |
Experience with hormonal therapy in advanced epithelial ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Carcinoma; Estrogen Antagonists; Female; Flutamide; Gonadotropin-Releasing Hormone; Humans; Luteolytic Agents; Medroxyprogesterone Acetate; Megestrol; Megestrol Acetate; Middle Aged; Ovarian Neoplasms; Progesterone Congeners; Remission Induction; Survival Rate; Tamoxifen; Triptorelin Pamoate | 1995 |
Metastatic carcinoma of the prostate presenting as a superior vena cava syndrome.
Topics: Adenocarcinoma; Aged; Biopsy; Flutamide; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Prostatic Neoplasms; Superior Vena Cava Syndrome; Time Factors; Triptorelin Pamoate | 1993 |
Combination therapy with flutamide and the LHRH agonist [D-Trp6, des-Gly-NH(2)10]LHRH ethylamide in stage C prostatic carcinoma.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Carcinoma; Drug Therapy, Combination; Flutamide; Gonadotropin-Releasing Hormone; Humans; Male; Middle Aged; Prostatic Neoplasms; Survival Rate; Triptorelin Pamoate | 1993 |
[Adenoid cystic carcinoma of the prostate. Clinical case].
Topics: Adenocarcinoma; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Biopsy; Carcinoma, Adenoid Cystic; Diagnosis, Differential; Flutamide; Gonadotropin-Releasing Hormone; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Triptorelin Pamoate | 2000 |
[Anemia and neoadjuvant hormone therapy in radical surgery of localized cancer of the prostate].
Topics: Androgen Antagonists; Anemia; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Flutamide; Hematocrit; Hemoglobins; Humans; Leuprolide; Male; Prostatic Neoplasms; Triptorelin Pamoate | 2001 |
Antagonists of growth hormone-releasing hormone (GH-RH) enhance tumour growth inhibition induced by androgen deprivation in human MDA-Pca-2b prostate cancers.
Topics: Androgen Antagonists; Animals; Antineoplastic Agents, Hormonal; Cell Division; Cell Line, Tumor; Drug Interactions; Flutamide; Growth Hormone-Releasing Hormone; Humans; Male; Mice; Mice, Nude; Prostatic Neoplasms; Random Allocation; Triptorelin Pamoate | 2004 |
Impact of neoadjuvant hormonal therapy on dose-volume histograms in patients with localized prostate cancer under radical radiation therapy.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Dose Fractionation, Radiation; Flutamide; Humans; Male; Middle Aged; Neoadjuvant Therapy; Prospective Studies; Prostatic Neoplasms; Radiotherapy Planning, Computer-Assisted; Triptorelin Pamoate | 2006 |
[Mediastinal lymph nodes during the course of a metastatic prostate cancer].
Topics: Adenocarcinoma; Androgen Antagonists; Androgens; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyproterone; Diphosphonates; Estramustine; Fatal Outcome; Flutamide; Humans; Imidazoles; Ketoconazole; Lung Neoplasms; Lymphatic Metastasis; Male; Mediastinum; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Radionuclide Imaging; Skin Neoplasms; Triptorelin Pamoate; Zoledronic Acid | 2007 |
PSA kinetics provide improved prediction of survival in metastatic hormone-refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flutamide; Humans; Kinetics; Male; Neoplasm Metastasis; Orchiectomy; Predictive Value of Tests; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Treatment Failure; Triptorelin Pamoate | 2008 |
[Spontaneous complete remission in two patients with chronic lymphocytic leukemia].
Topics: Adenocarcinoma; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Female; Flutamide; Humans; Incidental Findings; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocyte Count; Male; Middle Aged; Neoplasms, Multiple Primary; Prostatic Neoplasms; Remission, Spontaneous; Triptorelin Pamoate | 2011 |
Docetaxel followed by abiraterone in metastatic castration-resistant prostate cancer: efficacy and predictive parameters in a large single center cohort.
Topics: Aged; Androgen Antagonists; Androstenes; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Buserelin; Cohort Studies; Disease-Free Survival; Docetaxel; Flutamide; Humans; Leuprolide; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Nitriles; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Tosyl Compounds; Treatment Outcome; Triptorelin Pamoate | 2015 |